A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy
收藏DataCite Commons2025-10-17 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00004486/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to compare the survival of participants who receive chemotherapy and ramucirumab versus chemotherapy alone as second line treatment for NSCLC after prior first line platinum-based chemotherapy.
提供机构：
Vivli
创建时间：
2019-09-09
